IRVING, Texas—Reata Pharmaceuticals Inc., a biopharmaceutical company developing novel drugs for cancer, inflammation and neurodegenerative diseases, announced the closing of a $25 million private financing round. Reata plans to use the proceeds to advance its pipeline, including funding multiple Phase II studies of the company’s two lead development candidates, RTA 402 and RTA 744.  Each is a novel therapy that has achieved clinical proof-of-concept in high-value cancer indications.  RTA 402 is also in development for inflammatory disease indications including hepatitis and rheumatoid arthritis. In addition to these lead programs, Reata has a pipeline of preclinical candidates for cancer, inflammation and neurodegenerative diseases as well as an innovative discovery platform based on the concept of correcting protein misfolding through the use of small molecule chaperones.